A recent single-center, phase II, non-randomized trial examining treatment-naïve unresectable stage III/IV acral melanoma treated with camrelizumab, an anti-PD-1 agent, apatinib, a vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, and temozolomide demonstrated an ORR of 64%, with a DCR of 88% and median PFS of 18.4 months [52]. The gene discussed is KDR; the disease is acral lentiginous melanoma.